The renal urate transporter SLC17A1 locus: confirmation of association with gout
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6354
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The renal urate transporter SLC17A1 locus: confirmation of association with gout ; volume:14 ; number:2 ; day:27 ; month:4 ; year:2012 ; pages:1-8 ; date:4.2012
Arthritis Research & Therapy ; 14, Heft 2 (27.4.2012), 1-8, 4.2012
- Urheber
-
Hollis-Moffatt, Jade E.
- Beteiligte Personen und Organisationen
-
Phipps-Green, Amanda J.
Chapman, Brett
Jones, Gregory T.
van Rij, Andre
Gow, Peter J.
Harrison, Andrew A.
Highton, John
Jones, Peter B.
Montgomery, Grant W.
Stamp, Lisa K.
Dalbeth, Nicola
Merriman, Tony R.
SpringerLink (Online service)
- DOI
-
10.1186/ar3816
- URN
-
urn:nbn:de:1111-2016050321585
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:59 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hollis-Moffatt, Jade E.
- Phipps-Green, Amanda J.
- Chapman, Brett
- Jones, Gregory T.
- van Rij, Andre
- Gow, Peter J.
- Harrison, Andrew A.
- Highton, John
- Jones, Peter B.
- Montgomery, Grant W.
- Stamp, Lisa K.
- Dalbeth, Nicola
- Merriman, Tony R.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Association analysis of the SLC22A11 (organic anion transporter 4) and SLC22A12 (urate transporter 1) urate transporter locus with gout in New Zealand case-control sample sets reveals multiple ancestral-specific effects
Variation in serum urate levels in the absence of gout and urate lowering therapy
Familial early-onset hyperuricemia and gout associated with a newly identified dysfunctional variant in urate transporter ABCG2
Adherence with urate-lowering therapies for the treatment of gout
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Unraveling the pathological biomineralization of monosodium urate crystals in gout patients
The relationship between ferritin and urate levels and risk of gout
Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study
Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
Transport mechanism and structural pharmacology of human urate transporter URAT1
Genetic polymorphisms and decreased protein expression of ABCG2 urate transporters are associated with susceptibility to gout, disease severity and renal-overload hyperuricemia
Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout
Association analysis of the SLC22A11 (organic anion transporter 4) and SLC22A12 (urate transporter 1) urate transporter locus with gout in New Zealand case-control sample sets reveals multiple ancestral-specific effects
Variation in serum urate levels in the absence of gout and urate lowering therapy
Familial early-onset hyperuricemia and gout associated with a newly identified dysfunctional variant in urate transporter ABCG2
Adherence with urate-lowering therapies for the treatment of gout
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Unraveling the pathological biomineralization of monosodium urate crystals in gout patients
The relationship between ferritin and urate levels and risk of gout
Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study
Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
Transport mechanism and structural pharmacology of human urate transporter URAT1
Genetic polymorphisms and decreased protein expression of ABCG2 urate transporters are associated with susceptibility to gout, disease severity and renal-overload hyperuricemia
Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout
Association analysis of the SLC22A11 (organic anion transporter 4) and SLC22A12 (urate transporter 1) urate transporter locus with gout in New Zealand case-control sample sets reveals multiple ancestral-specific effects
Variation in serum urate levels in the absence of gout and urate lowering therapy
Familial early-onset hyperuricemia and gout associated with a newly identified dysfunctional variant in urate transporter ABCG2
Adherence with urate-lowering therapies for the treatment of gout
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Unraveling the pathological biomineralization of monosodium urate crystals in gout patients
The relationship between ferritin and urate levels and risk of gout
Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study
Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
Transport mechanism and structural pharmacology of human urate transporter URAT1
Genetic polymorphisms and decreased protein expression of ABCG2 urate transporters are associated with susceptibility to gout, disease severity and renal-overload hyperuricemia